Etude d’impact sur l’optimisation des horaires d’ouverture des bibliothèques territoriales

Inscrite dans une dynamique d’accompagnement méthodologique des collectivités territoriales engagée par le ministère de la Culture et de la Communication, cette étude fait suite à l’ouvrage Ouvrir grand la médiathèque, coédité par le ministère de la Culture et de la Communication et l’Association des bibliothécaires de France. Cette étude présente les bilans de projets d’aménagement des horaires d’ouverture des bibliothèques de six collectivités, en recueillant le point de vue de leurs usagers, des professionnels et des tutelles. Ces bilans sont confrontés aux retours d’expérience de 145 établissements interrogés dans le cadre d’une enquête en ligne. Elle confirme notamment que les effets de l\u27extension des horaires sont clairement positifs, mais que l\u27extension en elle-même ne suffit pas toujours à créer un effet durable et gagne à s\u27inscrire dans une démarche stratégique mobilisant d\u27autres leviers (réflexion sur les services). Par ailleurs, elle démontre que si la question des moyens financiers est importante, les difficultés d\u27application sont aussi d\u27ordre organisationnel et social

Image fusion and reconstruction of compressed data: A joint approach

International audienceIn the context of data fusion, pansharpening refers to the combination of a panchromatic (PAN) and a multispectral (MS) image, aimed at generating an image that features both the high spatial resolution of the former and high spectral diversity of the latter. In this work we present a model to jointly solve the problem of data fusion and reconstruction of a compressed image; the latter is envisioned to be generated solely with optical on-board instruments, and stored in place of the original sources. The burden of data downlink is hence significantly reduced at the expense of a more laborious analysis done at the ground segment to estimate the missing information. The reconstruction algorithm estimates the target sharpened image directly instead of decompressing the original sources beforehand; a viable and practical novel solution is also introduced to show the effectiveness of the approach

Single-ion lithium conducting polymers with high ionic conductivity based on borate pendant groups

This communication reports a family of single-ion lithium conducting polymer electrolytes based on highly delocalized borate groups is reported. The effect of the nature of the substituents on the boron atom on the ionic conductivity of the resultant methacrylic polymers was analyzed. To the best of our knowledge the lithium borate polymers endowed with flexible and electron-withdrawing substituents presents the highest ionic conductivity reported for a lithium single-ion conducting homopolymer (1.65×10−4 S cm−1 at 60 °C). This together with its high lithium transference number tLi+= =0.93 and electrochemical stability window of 4.2 V vs Li0/Li+ show promise for application in lithium batteries. To illustrate this, a lithium borate monomer was integrated into a single-ion gel polymer electrolyte which showed good performance on lithium symmetrical cells (<0.85 V at ±0.2 mA cm−2 for 175 h).This work was supported by a Grant for Basque Government through grant IT1309-19, and European Commission’s funded Marie Skłodowska-Curie project POLYTE-EID (project no. 765828) and Spanish MCIN/ AEI/ PID2020-119026GB-I00. G.G-G. is grateful to "Secretaría de Educación, Ciencia, Tecnología e Innovación" from Ciudad de México for the postdoctoral fellowship through grant (SECTEI/133/2019)

Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort

French Hospital Database on HIVInternational audienceBackgroundThe effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant. We assessed the impact of statin-based primary prevention on all-cause mortality among HIV-infected individuals.MethodsPatients were selected among controls from a multicentre nested case-control study on the risk of myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders were not eligible. Potential confounders, including variables that were associated either with statin use and/or death occurrence and statin use were evaluated within the last 3 months prior to inclusion in the case-control study. Using an intention to continue approach, multiple imputation of missing data, Cox’s proportional hazard models or propensity based weighting, the impact of statins on the 7-year all-cause mortality was evaluated.ResultsAmong 1,776 HIV-infected individuals, 138 (8%) were statins users. During a median follow-up of 53 months, 76 deaths occurred, including 6 in statin users. Statin users had more cardiovascular risk factors and a lower CD4 T cell nadir than statin non-users. In univariable analysis, the death rate was higher in statins users (11% vs 7%, HR 1.22, 95%CI 0.53-2.82). The confounders accounted for were age, HIV transmission group, current CD4 T cell count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies positivity, HBs antigen positivity, diabetes and hypertension. In the Cox multivariable model the estimated hazard ratio of statin on all-cause mortality was estimated as 0.86 (95%CI 0.34-2.19) and it was 0.83 (95%CI 0.51-1.35) using inverse probability treatment weights.ConclusionThe impact of statin for primary prevention appears similar in HIV-infected individuals and in the general population

Chikungunya Virus Infection during Pregnancy, Réunion, France, 2006

Except for prenatal hospital admissions for those infected, this virus had no effect on outcomes

Gaining Greater Insight into HCV Emergence in HIV-Infected Men Who Have Sex with Men: The HEPAIG Study

OBJECTIVES: The HEPAIG study was conducted to better understand Hepatitis C virus (HCV) transmission among human immuno-deficiency (HIV)-infected men who have sex with men (MSM) and assess incidence of HCV infection among this population in France. METHODS AND RESULTS: Acute HCV infection defined by anti-HCV or HCV ribonucleic acid (RNA) positivity within one year of documented anti-HCV negativity was notified among HIV-infected MSM followed up in HIV/AIDS clinics from a nationwide sampling frame. HIV and HCV infection characteristics, HCV potential exposures and sexual behaviour were collected by the physicians and via self-administered questionnaires. Phylogenetic analysis of the HCV-NS5B region was conducted. HCV incidence was 48/10 000 [95% Confidence Interval (CI):43-54] and 36/10 000 [95% CI: 30-42] in 2006 and 2007, respectively. Among the 80 men enrolled (median age: 40 years), 55% were HIV-diagnosed before 2000, 56% had at least one sexually transmitted infection in the year before HCV diagnosis; 55% were HCV-infected with genotype 4 (15 men in one 4d-cluster), 32.5% with genotype 1 (three 1a-clusters); five men were HCV re-infected; in the six-month preceding HCV diagnosis, 92% reported having casual sexual partners sought online (75.5%) and at sex venues (79%), unprotected anal sex (90%) and fisting (65%); using recreational drugs (62%) and bleeding during sex (55%). CONCLUSIONS: This study emphasizes the role of multiple unprotected sexual practices and recreational drugs use during sex in the HCV emergence in HIV-infected MSM. It becomes essential to adapt prevention strategies and inform HIV-infected MSM with recent acute HCV infection on risk of re-infection and on risk-reduction strategies

Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period

Objectives: People with HIV (PWH) are at an increased risk of atherosclerotic cardiovascular disease. Suboptimal responses to statin therapy in PWH may result from antiretroviral therapies (ARTs). This open-label extension study aimed to evaluate the long-term safety and efficacy of evolocumab up to 52\u200aweeks in PWH. Design: This final analysis of a multinational, placebo-controlled, double-blind, randomized phase 3 trial evaluated the effect of monthly subcutaneous evolocumab 420\u200amg on low-density lipoprotein cholesterol (LDL-C) during the open-label period (OLP) following 24\u200aweeks of double-blind period in PWH with hypercholesterolemia/mixed dyslipidemia. All participants enrolled had elevated LDL-C or nonhigh-density lipoprotein cholesterol (non-HDL-C) and were on stable maximally tolerated statin and stable ART. Methods: Efficacy was assessed by percentage change from baseline in LDL-C, triglycerides, and atherogenic lipoproteins. Treatment-emergent adverse events (TEAEs) were examined. Results: Of the 467 participants randomized in the double-blind period, 451 (96.6%) received at least one dose of evolocumab during the OLP (mean age of 56.4\u200ayears, 82.5% male, mean duration with HIV of 17.4\u200ayears). By the end of the 52-week OLP, the overall mean (SD) percentage change in LDL-C from baseline was -57.8% (22.8%). Evolocumab also reduced triglycerides, atherogenic lipid parameters (non-HDL-C, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, and lipoprotein[a]), and increased HDL-C. TEAEs were similar between placebo and evolocumab during the OLP. Conclusion: Long-term administration of evolocumab lowered LDL-C and non-HDL-C, allowing more PWH to achieve recommended lipid goals with no serious adverse events. Trail registration: NCT02833844. Video abstract: http://links.lww.com/QAD/C441